- ￥22
- ProSci
- 美国
- PSI-14-471-50uL
- 2025年07月13日
- WB,IHC,IF
- 兔
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant fusion protein containing a sequence corresponding to amino acids 1-424 of human MAPK9 (NP_002743.3).
- 保存条件：
Store at -20℃
- 保质期：
1年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 宿主：
兔
- 应用范围：
WB,IHC,IF
- 抗体英文名：
MAPK9 Antibody, KO Validated
- 抗体名：
MAPK9 Antibody, KO Validated
- 规格：
50uL
MAPK9 抗体, KO Validated，MAPK9 Antibody, KO Validated，MAPK9 抗体, KO Validated,MAPK9 Antibody, KO Validated
产品名称：MAPK9 抗体, KO Validated-MAPK9 Antibody, KO Validated
产品货号：PSI-14-471-50uL
产品规格：50uL
背景资料：The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase targets specific transcription factors, and thus mediates immediate-early gene expression in response to various cell stimuli. It is most closely related to MAPK8, both of which are involved in UV radiation induced apoptosis, thought to be related to the cytochrome c-mediated cell death pathway. This gene and MAPK8 are also known as c-Jun N-terminal kinases. This kinase blocks the ubiquitination of tumor suppressor p53, and thus it increases the stability of p53 in nonstressed cells. Studies of this gene's mouse counterpart suggest a key role in T-cell differentiation. Several alternatively spliced transcript variants encoding distinct isoforms have been reported.
保存建议：MAPK9 抗体, KO Validated-MAPK9 Antibody, KO ValidatedStore at -20℃
应用类型：WB,IHC,IF
点击：MAPK9 抗体, KO Validated-MAPK9 Antibody, KO Validated查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Methods 2016 年的文章2，国际抗体验证工作小组（International Working Group on Antibody Validation, IWGAV）提出 5 种支柱策略（conceptual pillar），如下：1. 基因策略（敲除验证）：利用 CRISPR/Cas 或 RNAi 等技术对靶基因进行敲除（knock out）或敲低（knock down），分别检测对照组与 KO 组的信号。2. 正交策略：在多种样品中使用一种与抗体无关的定量方法，然后比较分析基于抗体的定量
双特异抗体(Bispecific antibody)的简介和制作方法
、双特异抗体简介双特异抗体（Bispecific antibody）是含有两个不同配体结合位点的免疫球蛋白分子。自然状态下不存在双特异性抗体，只能通过特殊方法进行制备。以往双特异抗体的制备方法有化学交联法，杂合F（ab'）2 分子法和鼠杂交瘤法等。化学交联法生产双特异抗体的异源性，批与批之间的不稳定性，以及抗体特异性易受某些修饰或不当连接而改变的特性，使得该法生产的双特异抗体不适于体内使用。以巯基交联蛋白酶消化片断F（ab'）生产的双特异杂交分子，成分虽较均一，但费时费力，且产量很低。杂交瘤法生产
Improving Phage Display Throughput by Using Hyperphage, Miniaturized Titration and pVIII (g8p) ELISA
Hyperphage is a substitute for M13KO7 helper phage used in antibody phage display. It allows to improve the antibody display efficiency on phage by 2-3 orders of magnitude. This is achieved by forcing the packaging E. coli cell to exclusively
技术资料暂无技术资料 索取技术资料
